Megna Michael R

CHIEF ACCOUNTING OFFICERKiniksa Pharmaceuticals International, plc (KNSA) · full profile →Form 4 · filed Apr 8, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 7, 2026Option exercise(M)4K$1.00$4K36K
Apr 7, 2026Tax withholding(F)2K$48.94$82K34K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 7, 2026Option exercise(M)4K$00

Transaction Codes

M
Option exercise / conversion
F
Shares withheld for taxes

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001464583-26-000004) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Build on these Form 4 transactions

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.